Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05022017
Other study ID # EOS MODIC
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 3, 2021
Est. completion date April 26, 2023

Study information

Verified date April 2023
Source Groupe Hospitalier Paris Saint Joseph
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Inflammatory disc disease or Modic 1 disc disease is a radiological entity first described by Modic in 1988 and corresponds to an inflammatory signal on MRI defined by the presence of a T2-weighted hypersignal and a T1-weighted hyposignal of the vertebral endplates adjacent to a pathological disc. The presence of these radiological abnormalities are significantly associated with chronic low back pain, the therapeutic management of which may include lumbar rehabilitation, rigid corset, spinal infiltrations and surgical treatment. Corticosteroid infiltration of the pathological intervertebral disc (intradiscal infiltration) has been evaluated in low back pain due to Modic 1 disc disease with short-term efficacy. The clinical response to this infiltration is not always optimal and to date in the literature, no predictive factor of response has been identified.


Description:

There are several hypotheses to explain this phenomenon: mechanical, genetic, infectious or inflammatory. One of the mechanical hypotheses would be the presence of an instability of the spinal segment (hypermobility of the spinal segment) and disorders of the sagittal statics of the spine with angles of thoracic kyphosis and lumbar lordosis weak and a weak sacral slope supporting a hyperpressure passing by the discs and the genesis of discopathy. In this work, the investigators will evaluate the different parameters of the spinal statics in the sagittal plane and in the frontal plane (sacral slope, pelvic version, Roussouly classification, cobb angle...) by EOS imaging as well as the parameters of the Modic 1 anomaly on lumbar MRI (spinal stage, Pfirmann classification, laterality of the inflammatory signal) in a population of patients who received intradiscal corticosteroid infiltration for low back pain in the context of Modic 1 disc disease. The analysis of the different radiological parameters could enrich the investigator's understanding of the pathophysiology and evaluate radiological factors predictive of the effectiveness of intradiscal infiltration in this population. This could allow us to adapt the management of low back pain patients with Modic 1 disc disease.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date April 26, 2023
Est. primary completion date June 3, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient whose age = 18 years - French speaking patient - Patient hospitalized in the rheumatology department of GHPSJ between 01/01/2014 and 31/12/2020 for MODIC 1 - Patients who received as part of their management an intra-disc infiltration with hydrocortancyl. Exclusion Criteria: - Patient under guardianship or curators - Patient deprived of liberty - Patient under court protection - Patient objecting to the use of his data for this research - Patient having benefited from another infiltration between the intradiscal infiltration and the collection of efficacy data at 3 months.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Groupe Hospitalier Paris Saint Joseph Paris Ile-de-France

Sponsors (1)

Lead Sponsor Collaborator
Groupe Hospitalier Paris Saint Joseph

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate the effectiveness of the intra-disc infiltration at 3 months on the pain felt by the patient. Percentage of patients with improved low back pain defined as a decrease in Visual Analogue Scale (VAS) pain >3 at 3 months after intradiscal infiltration compared to VAS at admission.
VAS scale : minimum score 0 (no pain) / higher score 10 (greater pain intensity)
3 months
Secondary Change in analgesic consumption (Level 1, Level 2, Level 3 and NSAIDs) at 3 months. Consumption of level 1, 2 or 3 painkillers and NSAIDs in the previous week (number of doses per day and per week). 3 months
Secondary Describe the parameters of spinal statics in the frontal planes in Modic 1 disc disease. Distribution of the values of the parameters of the spinal statics in the sagittal plane (sacral slope, pelvic incidence, pelvic version, lumbar lordosis, Roussouly classification) and in the frontal plane (cobb angle). 3 months
Secondary Compare the parameters of spinal statics according to the different stages of Modic 1 disc disease Distribution of the values of spinal statics parameters in the sagittal plane (sacral slope, pelvic incidence, pelvic version, lumbar lordosis, Roussouly classification) and in the frontal plane (cobb angle) according to the presence of low lumbar (L4L5 L5S1) or high lumbar (L1L2 L2L3 L3L4) disc disease. 3 months
Secondary Predictive factors (clinical and radiological) of the effectiveness of intra-disc infiltration Correlation between pain improvement 3 months after infiltration and the type of disc disease (cobb scoliosis > 10°) as well as the parameters of spinal statics in the sagittal and frontal planes and the type of disc damage according to the Pfirmann classification 3 months
See also
  Status Clinical Trial Phase
Completed NCT03964324 - NO Measurements in Screening for Asthma and OSA, in Patients With Severe Snoring N/A
Recruiting NCT03963648 - NO Measurements in Screening for Asthma and OSA, in Patients With CRSwNP N/A
Not yet recruiting NCT04997343 - Neurophysiological Assessment in Patients With Multiple Sclerosis N/A
Completed NCT01695876 - A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects Phase 1
Not yet recruiting NCT05546788 - Hydroxylated Polymethoxy Flavones Solid Dispersion in Treatment of Periodontitis Phase 1
Recruiting NCT03651518 - Personalized Therapies in Inflammatory Complex Disease Phase 2
Not yet recruiting NCT05544448 - In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases N/A
Completed NCT02552004 - Assessment of Intraoperative Probe-based Confocal Laser Endomicroscopy in Digestive and Endocrine Surgery: a Pilot Study N/A
Completed NCT04368494 - Exercise Therapy in Patients With Axial Spondyloarthritis N/A
Completed NCT03878134 - Translational Development of Photon-counting CT Imaging N/A
Recruiting NCT06059989 - inDuctIon tREatment With subCuTaneous Infliximab for Crohn's Disease Phase 3
Completed NCT02959138 - Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function Phase 1
Active, not recruiting NCT04565821 - Feasibility Study to Assess a Trans-nasal Intestinal Potential Difference Probe N/A
Recruiting NCT05509075 - Nutraceuticals and Functional Foods
Active, not recruiting NCT06448052 - Umbilical Cord Mesenchymal Stem Cell for Aging-related Low-grade Inflammation Phase 1/Phase 2
Active, not recruiting NCT05944822 - Pro-inflammatory Cytokines in Case of Essure®
Completed NCT05115370 - Vaccination Perception in Inflammatory Conditions - Flu, Pneumonia and COVID-19
Active, not recruiting NCT03604406 - The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept Phase 2
Recruiting NCT05364294 - Molecular Diagnosis of Systemic Autoinflammatory Diseases
Recruiting NCT05860400 - Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study